Lead Investigator: Joan Busner, Signant Health
Title of Proposal Research: Psychometric evaluation of Positive and Negative Syndrome Scale (PANSS) in adolescent schizophrenia trials
Vivli Data Request: 7145
Funding Source: None
Potential Conflicts of Interest: Employee of Signant Health, a company that provides scientific support for clinical trials. Findings from the research will be presented in a manner that is fair, balanced, scientifically rigorous, and free of promotional bias.
Signant Health is providing funding for the statistical analyses. Research findings will be presented in a fair and non promotional manner.
Summary of the Proposed Research:
The 30 item Positive and Negative Syndrome Scale (PANSS) is a widely used primary efficacy scale in schizophrenia trials. It was used in the aripiprazole trial referenced above.
The PANSS was developed for adults and takes a substantial amount of interview time. The psychometrics of the scale have not been well explored in adolescent samples. Our group is working to develop a psychometrically sound shorter form. A shorter form PANSS that concentrated on the most helpful items would reduce burden for participants, as well as training and administration costs for researchers. A shorter form also would be helpful in clinical applications.
Aripiprazole in Adolescents With Schizophrenia
Data Contributor: Otsuka Pharmaceuticals
Study ID: NCT00102063
Sponsor ID: 31-03-239